Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Rating of “Moderate Buy” from Brokerages

Abivax SA Sponsored ADR (NASDAQ:ABVX) has earned an average recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $128.7273.

A number of equities research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, October 8th. Truist Financial set a $140.00 price target on shares of Abivax in a research note on Monday, November 24th. Wall Street Zen downgraded shares of Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. JMP Securities lifted their target price on shares of Abivax from $95.00 to $114.00 and gave the stock a “market outperform” rating in a report on Thursday, September 25th. Finally, Guggenheim reiterated a “buy” rating and issued a $175.00 target price on shares of Abivax in a research note on Thursday, December 18th.

Abivax Price Performance

ABVX stock opened at $142.31 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. The firm has a 50 day moving average price of $113.55 and a 200-day moving average price of $76.11. Abivax has a 52-week low of $4.77 and a 52-week high of $148.83. The firm has a market capitalization of $11.09 billion, a price-to-earnings ratio of -34.05 and a beta of 0.48.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The company had revenue of ($4.92) million during the quarter. Equities research analysts forecast that Abivax will post -2.83 EPS for the current fiscal year.

Institutional Trading of Abivax

Institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its stake in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares during the last quarter. Affinity Asset Advisors LLC purchased a new stake in shares of Abivax during the first quarter valued at $1,250,000. Cubist Systematic Strategies LLC increased its holdings in Abivax by 34.3% in the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after buying an additional 2,595 shares in the last quarter. Nantahala Capital Management LLC raised its position in Abivax by 3.3% in the 1st quarter. Nantahala Capital Management LLC now owns 1,482,994 shares of the company’s stock worth $9,269,000 after buying an additional 46,947 shares during the last quarter. Finally, Paloma Partners Management Co purchased a new position in Abivax in the 1st quarter worth about $240,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.